Xconomy Forum: San Diego Life Sciences 2030

San Diego biotech has taken its share of lumps lately, but beyond the next quarter or next year, what kind of life sciences potential really exists here? What will the San Diego life sciences landscape look like 20 years from now? Will the region have grown as a world leader in university and corporate research, venture financing, and entrepreneurial activity? Which particular fields of life sciences and healthcare will be the most vibrant? We will bring together a select group of innovators and visionaries for an intimate, interactive discussion of these and other key questions about the future of San Diego-area life sciences.

Welcoming Remarks:

  • John Dunn, Executive Vice President, Biogen Idec New Ventures


  • John Mendlein (moderator), Chairman of the Board, Fate Therapeutics
  • Paul Schimmel, Professor of Chemical Biology, The Scripps Research Institute; Cofounder or founding director of eleven biotechnology companies, of which six (Alkermes, Alnylam Pharmaceuticals, Avicena Group, Cubist Pharmaceuticals, Momenta Pharmaceuticals, Repligen Corporation) are publicly traded.
  • Dan Bradbury, President and CEO, Amylin Pharmaceuticals; Chairman of BIOCOM
  • Fred “Rusty” Gage, Professor and Vi and John Adler Chair for Research on Age-Related Neurodegenerative Diseases, Salk Institute for Biological Studies

Bonus Feature: Meet top executives from emerging life sciences enterprises, who will provide brief introductions to their organizations.

  • Ambrx
  • Biogen Idec New Ventures
  • Helixis
  • Receptos
  • VentiRx Pharmaceuticals

Registration Opens: 5:15 pm
Program: 6:00 pm – 7:30 pm
Reception: 7:30 pm – 8:30 pm

To register, click here.

Tickets are transferable but not refundable.
To inquire about press registration, email [email protected].

Xconomy Forum: San Diego Life Sciences 2030


Biogen Idec


Biogen Idec New Ventures

Fish & Richardson